Clinical Scorecard: Invikafusp alfa (invika) in immunotherapy-resistant cancers: early clinical trial findings

At a Glance

Key Highlights

• Across both trial phases, 27 participants received the optimal dose; disease progression was absent in 16 (59.3%).
• Tumor reductions exceeding 30% occurred in four participants (14.8%) who received the optimal dose.
• Two responders had metastatic colorectal cancer and were receiving invika as seventh-line therapy; another had stage 4 non-small cell lung cancer.
• Several participants experienced anticipated flu-like side effects, typically manageable with additional medication and supportive care.
• The investigators cautioned that immune activation did not necessarily produce measurable clinical benefit; the findings remain preliminary.

Guideline-Based Recommendations

Diagnosis

• The article reports enrollment of patients with diverse cancers, most of which had responded poorly to immune checkpoint blockade; it does not provide diagnostic criteria.

Management

• During phase 1, participants received different doses every two weeks to assess safety and establish an optimal dose; phase 2 used the identified optimal dose.
• The article describes invika as investigational and reports that the trial remains open to enrollment.

Monitoring & Follow-up

• Investigators assessed safety and dose effects and measured tumor size and disease progression.
• Investigators reported expansion of targeted T-cell populations; the four cases of tumor shrinkage were associated with the greatest changes in those populations.

Risks

• Several participants developed anticipated flu-like side effects, typically manageable with additional medication and supportive care.
• The article cautions that immune activation does not necessarily produce patient benefit.

Patient & Prescribing Data

Trial participants had diverse cancers, most of which had responded poorly to immune checkpoint blockade. Across both phases, 27 participants received the optimal dose; 16 had no disease progression and four had tumor reductions exceeding 30%.

During phase 1, invika was administered every two weeks at different doses; phase 2 used the identified optimal dose. The article reports no significant apparent benefit among participants given non-optimal doses and provides no routine-care prescribing regimen.

Clinical Best Practices

• The article characterizes the findings as preliminary phase 1 and early phase 2 evidence, not established treatment guidance.
• The article reports that immune activity did not invariably produce measurable clinical response.
• For trial participation information, the article directs interested individuals to the National Cancer Institute.

Related Resources & Content

• National Cancer Institute clinical trials information